Aditxt, Inc. (NASDAQ: ADTX) stock remained comparatively stable with a -3.10% decline to conclude the Thursday session at $1.25. That followed a robust surge in ADTX stock when it witnessed a notable increase during the Wednesday session, driven by a significant development from its subsidiary. The share price of ADTX climbed 31.63% on the day to conclude at $1.29.
Strategic Initiative by Pearsanta, Inc.
Pearsanta, Inc., a subsidiary of Aditxt, filed a proposal to the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) for the Clinical Trial Translational Endpoints Research Award. The goal of this project is to validate a novel assay that uses Pearsanta’s patented Mitomic Technology in order to help with early ovarian cancer diagnosis.
Addressing a Critical Health Need
Aditxt-subsidiary highlights a key deficiency in diagnostic capacities when she claims that current blood tests are not sensitive enough to detect ovarian cancer early enough. With the use of the unique properties of mitochondrial DNA (mtDNA), Pearsanta’s Mitomic Technology Platform makes non-invasive, blood-based liquid biopsies for the diagnosis of illness possible.
This technology is designed to identify specific mtDNA mutations indicative of various diseases. Given the high mutation rate and persistence of mtDNA, Pearsanta views it as an excellent biomarker for early disease detection. The platform facilitates the rapid and precise identification of biomarkers associated with disease, thereby significantly improving early diagnosis and treatment prospects.
Pearsanta’s current focus includes developing tests for the early detection of ovarian, prostate, and lung cancers, as well as for non-cancerous conditions like endometriosis. The proposal to CDMRP centers on validating the Mitomic Ovarian Test (MOT), which uses mtDNA mutations as early indicators of ovarian cancer. If successful, this technology could transition to public health funding agencies such as BARDA, indicating its potential for broad public health application.
The goal is to develop a reliable blood test capable of detecting ovarian cancer at its earliest stages, thereby enhancing treatment outcomes and survival rates. In response to the CDMRP’s award, Pearsanta has initiated a prospective cohort study to collect blood samples and clinical data from patients undergoing surgery for ovarian cancer diagnosis.
